Jingtao Wu

发表

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Jennifer G. Robinson, Alex A. Knopman, D. Rujescu, 2021, The Lancet Neurology.

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

Deepak L. Bhatt, A. Michelson, A. L. Frelinger, 2013, Journal of the American College of Cardiology.

The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.

H. Naik, L. Gunawardhana, M. Tsai, 2012, International journal of clinical pharmacology and therapeutics.

Copyright Informa UK Limited 2009 Not for Sale or Comercial Distribution

D. Mulford, Jing-tao Wu, Weijiang Zhang, 2009 .

Population Pharmacokinetics and Exposure‐Response of a Fixed‐Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension

M. Vakilynejad, S. Kupfer, M. Tsai, 2016, Journal of clinical pharmacology.

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

Ronald D Lee, Deepak L. Bhatt, Deepak L Bhatt, 2012, Journal of the American College of Cardiology.

Effects of Dexlansoprazole MR, a Novel Dual Delayed Release Formulation of a Proton Pump Inhibitor, on Plasma Gastrin Levels in Healthy Subjects

Jing-tao Wu, Weijiang Zhang, S. Atkinson, 2009, Journal of clinical pharmacology.

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

M. Jeong, Jing-tao Wu, A. Juhasz, 2018, Clinical Hypertension.

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.

W. Cushman, G. Bakris, W. White, 2018, The American journal of cardiology.

Orexin 2 receptor‐selective agonist danavorexton (TAK‐925) promotes wakefulness in non‐human primates and healthy individuals

Yaming Hang, H. Faessel, H. Yukitake, 2023, Journal of sleep research.

The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

H. Naik, L. Mclean, R. Palmer, 2012, British journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials*

D. Mulford, Jing-tao Wu, Weijiang Zhang, 2009 .

Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation

L. Gunawardhana, R. Lee, D. Mulford, 2009, Clinical Drug Investigation.

Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

D. Mulford, Weijiang Zhang, M. Vakily, 2009, Current medical research and opinion.

TAK-390MR, a Novel Dual Delayed Release Formulation of a PPI, Is Bioequivalent When Administered as Granules Sprinkled Over Applesauce or as an Intact Capsule: 12

R. Czerniak, M. Vakily, Jingtao Wu, 2008 .

Lack of Electrocardiographic Effect of Dexlansoprazole MR, a Novel Modified‐Release Formulation of the Proton Pump Inhibitor Dexlansoprazole, in Healthy Participants

Jing-tao Wu, M. Vakily, S. Atkinson, 2009, Journal of clinical pharmacology.

Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator

H. Faessel, R. Alexander, L. Rosen, 2019 .

TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM

K. Welsh-Bohmer, A. Saunders, J. Burke, 2019, Alzheimer's & Dementia.

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function

A. Michelson, Michael Lampa, M. Barnard, 2012 .

A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

S. Touno, H. Faessel, R. Alexander, 2019 .

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers

H. Naik, M. Vakilynejad, T. Higuchi, 2012, Journal of clinical pharmacology.

Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level–dependent functional magnetic resonance imaging study in elderly adults

Annchen R. Knodt, A. Hariri, K. Welsh-Bohmer, 2019, Alzheimer's & dementia.

A human [11C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor

Vladimir Stepanov, Akihiro Takano, Paul Goldsmith, 2016, NeuroImage.

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension

Q. Lv, M. Long, Wei Zhou, 2020, Medicine.